Cytosorbents Crp (CTSO) - Total Liabilities
Based on the latest financial reports, Cytosorbents Crp (CTSO) has total liabilities worth $36.73 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Cytosorbents Crp generate cash to assess how effectively this company generates cash.
Cytosorbents Crp - Total Liabilities Trend (2004–2024)
This chart illustrates how Cytosorbents Crp's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Cytosorbents Crp to evaluate the company's liquid asset resilience ratio.
Cytosorbents Crp Competitors by Total Liabilities
The table below lists competitors of Cytosorbents Crp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Heramed Ltd
AU:HMD
|
Australia | AU$658.25K |
|
Altamira Gold Corp
V:ALTA
|
Canada | CA$563.40K |
|
Augwind Energy Tech Storage Ltd
TA:AUGN
|
Israel | ILA12.78 Million |
|
Advanced Braking Technology Ltd
AU:ABV
|
Australia | AU$3.96 Million |
|
enX Group Ltd
JSE:ENX
|
South Africa | ZAC604.02 Million |
|
Uniti SA
PA:ALUNT
|
France | €297.93 Million |
|
Watos Corea Co. Ltd
KQ:079000
|
Korea | ₩4.35 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Cytosorbents Crp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTSO market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.80 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cytosorbents Crp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cytosorbents Crp (2004–2024)
The table below shows the annual total liabilities of Cytosorbents Crp from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.26 Million | +20.94% |
| 2023-12-31 | $29.99 Million | +7.64% |
| 2022-12-31 | $27.86 Million | +3.40% |
| 2021-12-31 | $26.94 Million | +150.97% |
| 2020-12-31 | $10.73 Million | -55.21% |
| 2019-12-31 | $23.96 Million | +51.56% |
| 2018-12-31 | $15.81 Million | +14.25% |
| 2017-12-31 | $13.84 Million | +36.12% |
| 2016-12-31 | $10.17 Million | +234.06% |
| 2015-12-31 | $3.04 Million | -32.45% |
| 2014-12-31 | $4.51 Million | -75.39% |
| 2013-12-31 | $18.31 Million | +22.36% |
| 2012-12-31 | $14.96 Million | +729.43% |
| 2011-12-31 | $1.80 Million | -21.44% |
| 2010-12-31 | $2.30 Million | +136.57% |
| 2009-12-31 | $970.76K | -5.54% |
| 2008-12-31 | $1.03 Million | +13.32% |
| 2007-12-31 | $906.87K | -16.19% |
| 2006-12-31 | $1.08 Million | +961.13% |
| 2005-12-31 | $101.97K | +13.30% |
| 2004-12-31 | $90.00K | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflamm… Read more